drugset / Trial / NCT00145600

Therapy for Pediatric Hodgkin Lymphoma

NCT00145600

Phase 2 Completed 296 enrolled St. Jude Children's Research Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.

Timeline

Start
2000-03-02
Primary completion
2012-05-31
Completion
2021-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified
Subject Methotrexate Small molecule
Subject Prednisone Other / unclassified
Subject Vinblastine Small molecule

Indications